


## AMENDMENTS TO THE CLAIMS

Claims 1-50 (Canceled)

51. (New) A method for preparing an oxazolidinone derivative of Formula (I):



Formula (I)

or a pharmaceutically acceptable salt thereof

wherein,

R<sub>1</sub> and R'<sub>1</sub> are independently hydrogen or fluorine;

R<sub>2</sub> is -NR<sub>5</sub>R<sub>6</sub>, -OR<sub>7</sub>, fluorine, alkylphosphate, monophosphate or a metal salt of monophosphate;

R<sub>5</sub> and R<sub>6</sub> are independently hydrogen or C<sub>1-4</sub> alkyl;


R<sub>7</sub> is hydrogen, C<sub>1-3</sub> alkyl or acylated amino acid, wherein the amino acid is alanine, glycine, proline, isoleucine, leucine, phenylalanine, β-alanine or valine;

R<sub>3</sub> is hydrogen, C<sub>1-4</sub> alkyl group that is unsubstituted, or substituted with cyano, -(CH<sub>2</sub>)<sub>m</sub>-OR<sub>7</sub> or ketone; and

m is 0, 1, 2, 3, or 4;


the method comprises the steps of:

reacting a compound of Formula (III) wherein Y is halogen:




Formula (III)

with a tin compound to provide a compound of Formula (IV) wherein Z is C<sub>1-4</sub> alkyl:




Formula (IV);

reacting the compound of Formula (IV) with a compound of Formula (VI):



Formula (VI)

under conditions selected to give a compound of Formula (V):




Formula (V); and

optionally reacting the compound of Formula (V) under conditions selected to give the compound of Formula (I).

52. (New) The method of Claim 51, comprising reacting the compound of Formula (V) under conditions selected to give the compound of Formula (I), wherein the reacting step further comprises the compound of Formula (V) under conditions to convert the R<sub>2</sub> hydroxyl group of Formula (V) to R<sub>2</sub> selected from the group consisting of -NR<sub>5</sub>R<sub>6</sub>, -OR<sub>7</sub>, fluorine, alkylphosphate, monophosphate and a metal salt of the monophosphate of the compound of Formula (I).

53. (New) A method for preparing an oxazolidinone derivative of Formula (I):



Formula (I)

or a pharmaceutically acceptable salt thereof

wherein,

R<sub>1</sub> and R'<sub>1</sub> are independently hydrogen or fluorine;

R<sub>2</sub> is -NR<sub>5</sub>R<sub>6</sub>, -OR<sub>7</sub>, fluorine, alkylphosphate, monophosphate or a metal salt of monophosphate;

R<sub>5</sub> and R<sub>6</sub> are independently hydrogen or C<sub>1-4</sub> alkyl;


R<sub>7</sub> is C<sub>1-3</sub> alkyl or acylated amino acid, wherein the amino acid is alanine, glycine, proline, isoleucine, leucine, phenylalanine, β-alanine or valine;

R<sub>3</sub> is hydrogen, C<sub>1-4</sub> alkyl group that is unsubstituted, or substituted with cyano, -(CH<sub>2</sub>)<sub>m</sub>-OR<sub>7</sub> or ketone; and

m is 0, 1, 2, 3, or 4;

wherein the method comprises:

reacting the R<sub>2</sub> hydroxy group of Formula (V)



Formula (V)

under conditions selected to give R<sub>2</sub> selected from the group consisting of -NR<sub>5</sub>R<sub>6</sub>, -OR<sub>7</sub>, fluorine, alkylphosphate, monophosphate and a metal salt of monophosphate.

54. (New) The method of Claim 53,

wherein the alkylphosphate is ditetrabutylester.

55. (New) The method of Claim 53, further comprising

reacting the compound of Formula (I), wherein  $R_7$  is the acylated amino acid, with an acid under conditions selected to form a pharmaceutically acceptable salt.

56. (New) The method of Claim 56, wherein the acid is hydrochloric acid or trifluoroacetic acid.

57. (New) The method of Claim 53, wherein the reacting step comprises reacting the compound of Formula (V) with phosphorous oxy chloride to give the compound of Formula (I) wherein  $R_2$  is monophosphate.

58. (New) The method of Claim 53, wherein the reacting step comprises reacting the compound of Formula (I) wherein  $R_2$  is monophosphate with a metallic salt to give the compound of Formula (I) wherein  $R_2$  is a metal salt of the monophosphate or a disodium salt of the monophosphate.

59. (New) The method of Claim 53, wherein  $R_1$  is hydrogen and  $R_1'$  is fluorine.

60. (New) The method of Claim 53, wherein  $R_2$  is  $-OR_7$  and  $R_7$  is the acylated amino acid.

61. (New) The method of Claim 53, wherein  $R_2$  is selected from the group consisting of alkylphosphate, monophosphate and a metal salt of the monophosphate.

62. (New) The method of Claim 53, wherein  $R_3$  is methyl.

63. (New) The method of Claim 53, wherein the compound of Formula (I) is selected from the group consisting of

Compound 12) (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-glycyloxymethyl oxazolidin-2-one trifluoroacetic acid;

Compound 18) (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-fluoromethyl oxazolidin-2-one;

Compound 20) (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-(L-valyloxy)methyl oxazolidin-2-one trifluoroacetic acid;

Compound 33) (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-methoxymethyl oxazolidin-2-one;

Compound 38) (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3,5-difluorophenyl)-5-hydroxymethyl oxazolidin-2-one;

Compound 40) (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-(N,N-dimethylaminomethyl)oxazolidin-2-one;

Compound 41) (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-(N-methylaminomethyl)oxazolidin-2-one;

Compound 42) (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-(L-alanyloxy)methyl oxazolidin-2-one trifluoroacetic acid;

Compound 43) (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-(L-valyloxy)methyl oxazolidin-2-one hydrochloride;

Compound 44) (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-(L-alanyloxy)methyl oxazolidin-2-one hydrochloride;

Compound 45) (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-glycyloxymethyl oxazolidin-2-one hydrochloride;

Compound 46) (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-(L-prolinyloxy)methyl oxazolidin-2-one trifluoroacetic acid;

Compound 47) (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-(L-prolinyloxy)methyl oxazolidin-2-one hydrochloride;

Compound 49) (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-( $\beta$ -alanyloxy)methyl oxazolidin-2-one trifluoroacetic acid;

Compound 50) (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-( $\beta$ -alanyloxy)methyl oxazolidin-2-one hydrochloride;

Compound 59) (R)-[3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl disodiumphosphate;

Compound 61) (R)-3-(4-(2-(1-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one;

Compound 62) (R)-3-(4-(2-(1-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-glycyloxymethyl oxazolidin-2-one trifluoroacetic acid;

Compound 63) (R)-3-(4-(2-(1-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-glycyloxymethyl oxazolidin-2-one hydrochloride;

Compound 64) (R)-3-(4-(2-(1-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-(L-alanyloxy)methyl oxazolidin-2-one trifluoroacetic acid;

Compound 65) (R)-3-(4-(2-(1-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-(L-alanyloxy)methyl oxazolidin-2-one hydrochloride;

Compound 66) (R)-3-(4-(2-(1-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-(L-valyloxy)methyl oxazolidin-2-one trifluoroacetic acid;

Compound 67) (R)-3-(4-(2-(1-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-(L-valyloxy)methyl oxazolidin-2-one hydrochloride;

Compound 68) (R)-3-(4-(2-(1-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-( $\beta$ -alanyloxy)methyl oxazolidin-2-one trifluoroacetic acid;


Compound 69) (R)-3-(4-(2-(1-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-( $\beta$ -alanyloxy)methyl oxazolidin-2-one hydrochloride;

Compound 70) (R)-[3-(4-(2-(1-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl disodiumphosphate;

Compound 72) mono-[(R)-[3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl] phosphate; and

Compound 73) mono-[(R)-[3-(4-(2-(1-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl] phosphate.


64. (New) The method of Claim 53, wherein the compound of Formula (I) has the structure



wherein R<sub>2</sub> is an alkylphosphate, a monophosphate, or a metal salt of the monophosphate.


65. (New) The method of Claim 64, wherein the compound has *R* stereochemistry.

66. (New) The method of Claim 53, wherein the compound of Formula (I) has the structure




wherein R<sub>2</sub> is an alkylphosphate, a monophosphate, or a metal salt of the monophosphate.

67. (New) The method of Claim 66, wherein the compound has *R* stereochemistry.
68. (New) The method of Claim 53, wherein the compound of Formula (I) has the structure




wherein R<sub>2</sub> is an alkylphosphate, a monophosphate or a metal salt of the monophosphate.

69. (New) The method of Claim 68, wherein the compound has *R* stereochemistry.
70. (New) The method of Claim 53, wherein the compound of Formula (I) has the structure




wherein R<sub>2</sub> is an alkylphosphate, a monophosphate, or a metal salt of the monophosphate.


71. (New) The method of Claim 70, wherein the compound has *R* stereochemistry.
72. (New) The method of Claim 53, wherein the compound of Formula (I) is



73. (New) The method of Claim 53, wherein the compound of Formula (I) is



74. (New, Withdrawn) An oxazolidinone derivative of Formula (I), or a pharmaceutically acceptable salt thereof:



Formula (I)

wherein,

R<sub>1</sub> and R'<sub>1</sub> are independently hydrogen or fluorine;

R<sub>2</sub> is -NR<sub>5</sub>R<sub>6</sub>, -OR<sub>7</sub>, fluorine, alkylphosphate, monophosphate or a metal salt of phosphate;

R<sub>5</sub> and R<sub>6</sub> are independently hydrogen or C<sub>1-4</sub> alkyl;

R<sub>7</sub> is hydrogen, C<sub>1-3</sub> alkyl or acylated amino acid, wherein the amino acid is alanine, glycine, proline, isoleucine, leucine, phenylalanine, β-alanine or valine;

R<sub>3</sub> is hydrogen, C<sub>1-4</sub> alkyl group that is unsubstituted, or substituted with cyano, -(CH<sub>2</sub>)<sub>m</sub>-OR<sub>7</sub> or ketone; and

m is 0, 1, 2, 3, or 4.



75. (New, Withdrawn) The compound of Claim 74, wherein  $R_1$  is hydrogen and  $R_1'$  is fluorine.

76. (New, Withdrawn) The compound of Claim 74, wherein  $R_2$  is -OH.

77. (New, Withdrawn) The compound of Claim 74, wherein  $R_2$  is -OR<sub>7</sub> and  $R_7$  is the acylated amino acid.

78. (New, Withdrawn) The compound of Claim 74, wherein  $R_2$  is selected from the group consisting of alkylphosphate, monophosphate and a metal salt of the monophosphate.

79. (New, Withdrawn) The compound of Claim 74, wherein  $R_3$  is methyl.

80. (New, Withdrawn) The compound of Claim 74, wherein the pharmaceutically acceptable salt is formed with an acid selected from the group consisting of hydrochloric acid, bromic acid, sulfuric acid, phosphoric acid, citric acid, acetic acid, lactic acid, maleic acid, fumaric acid, gluconic acid, methane sulfonic acid, glyeonic acid, succinic acid, 4-toluenesulfonic acid, trifluoroacetic acid, galuturonic acid, embonic acid, glutamic acid and aspartic acid.

81. (Previously Presented) The compound of Claim 80, wherein the acid is hydrochloric acid or trifluoroacetic acid.

82. (Previously Presented) The compound of Claim 74, which is selected from the group consisting of

Compound 10) (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one;

Compound 12) (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-glycyloxymethyl oxazolidin-2-one trifluoroacetic acid;

Compound 18) (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-fluoromethyl oxazolidin-2-one;

Compound 20) (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-(L-valyloxy)methyl oxazolidin-2-one trifluoroacetic acid;

Compound 33) (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-methoxymethyl oxazolidin-2-one;

Compound 38) (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3,5-difluorophenyl)-5-hydroxymethyl oxazolidin-2-one;

Compound 40) (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-(N,N-dimethylaminomethyl)oxazolidin-2-one;

Compound 41) (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-(N-methylaminomethyl)oxazolidin-2-one;

Compound 42) (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-(L-alanyloxy)methyl oxazolidin-2-one trifluoroacetic acid;

Compound 43) (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-(L-valyloxy)methyl oxazolidin-2-one hydrochloride;

Compound 44) (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-(L-alanyloxy)methyl oxazolidin-2-one hydrochloride;

Compound 45) (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-glycyloxymethyl oxazolidin-2-one hydrochloride;

Compound 46) (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-(L-prolinyloxy)methyl oxazolidin-2-one trifluoroacetic acid;

Compound 47) (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-(L-prolinyloxy)methyl oxazolidin-2-one hydrochloride;

Compound 49) (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-( $\beta$ -alanyloxy)methyl oxazolidin-2-one trifluoroacetic acid;

Compound 50) (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-( $\beta$ -alanyloxy)methyl oxazolidin-2-one hydrochloride;

Compound 59) (R)-[3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl disodiumphosphate;

Compound 61) (R)-3-(4-(2-(1-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one;

Compound 62) (R)-3-(4-(2-(1-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-glycyloxymethyl oxazolidin-2-one trifluoroacetic acid;

Compound 63) (R)-3-(4-(2-(1-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-glycyloxymethyl oxazolidin-2-one hydrochloride;

Compound 64) (R)-3-(4-(2-(1-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-(L-alanyloxy)methyl oxazolidin-2-one trifluoroacetic acid;

Compound 65) (R)-3-(4-(2-(1-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-(L-alanyloxy)methyl oxazolidin-2-one hydrochloride;

Compound 66) (R)-3-(4-(2-(1-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-(L-valyloxy)methyl oxazolidin-2-one trifluoroacetic acid;

Compound 67) (R)-3-(4-(2-(1-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-(L-valyloxy)methyl oxazolidin-2-one hydrochloride;

Compound 68) (R)-3-(4-(2-(1-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-( $\beta$ -alanyloxy)methyl oxazolidin-2-one trifluoroacetic acid;


Compound 69) (R)-3-(4-(2-(1-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-( $\beta$ -alanyloxy)methyl oxazolidin-2-one hydrochloride;

Compound 70) (R)-[3-(4-(2-(1-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl disodiumphosphate;

Compound 72) mono-[(R)-[3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl] phosphate; and

Compound 73) mono-[(R)-[3-(4-(2-(1-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl] phosphate.

83. (New, Withdrawn) The compound of Claim 74, having the structure




wherein  $R_2$  is hydroxyl, an alkylphosphate, a monophosphate, or a metal salt of the monophosphate.

84. (New, Withdrawn) The compound of Claim 83, wherein  $R_2$  is hydroxyl, the monophosphate, or a disodium salt of the monophosphate.


85. (New, Withdrawn) The compound of Claim 83, which has *R* stereochemistry.

86. (New, Withdrawn) The compound of Claim 74, having the structure




wherein  $R_2$  is hydroxyl, an alkylphosphate, a monophosphate, or a metal salt of the monophosphate.

87. (New, Withdrawn) The compound of Claim 86, which has *R* stereochemistry.  
88. (New, Withdrawn) The compound of Claim 74, having the structure




wherein  $R_2$  is hydroxyl, an alkylphosphate, a monophosphate or a metal salt of the monophosphate.

89. (New, Withdrawn) The compound of Claim 88, which has *R* stereochemistry.  
90. (New, Withdrawn) The compound of Claim 74, having the structure




wherein  $R_2$  is hydroxyl, an alkylphosphate, a monophosphate, or a metal salt of the monophosphate.


91. (New, Withdrawn) The compound of Claim 90, which has *R* stereochemistry.  
92. (New, Withdrawn) A compound having the formula



93. (New, Withdrawn) A compound having the formula



94. (New, Withdrawn) A compound having the formula



95. (New, Withdrawn) A pharmaceutical composition comprising the compound of Claim 74.

96. (New, Withdrawn) A method of treating a bacterial infection in a subject, comprising administering to the subject the compound of Claim 74.

97. (New, Withdrawn) The method of Claim 95, wherein the bacterial infection results from a Gram-positive bacterium.

98. (New, Withdrawn) The method of Claim 96, wherein the Gram-positive bacterium is selected from the group consisting of *Staphylococcus*, *Enterococcus*, *Streptococcus*, *Bacteroides*, *Clostridium*, and *Mycobacterium*.

99. (New, Withdrawn) The method of Claim 97, wherein the bacterium is selected from the group consisting of *Staphylococcus*, *Enterococcus*, and *Streptococcus*.